Navigation Links
Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
Date:12/8/2012

COLUMBUS, Ohio Updated results from a Phase Ib/II clinical trial indicates that a novel therapeutic agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy.

The agent, ibrutinib (PCI-32765), is the first drug designed to target Bruton's tyrosine kinase (BTK), a protein essential for CLL-cell survival and proliferation. CLL is the most common form of leukemia, with about 15,000 new cases annually in the U.S. About 4,400 Americans die of the disease each year.

Study co-leader Dr. John C. Byrd, director of the division of hematology at Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) presented these findings today (12/8) at the 54th Annual Meeting of the American Society of Hematology (ASH) Annual Meeting in Atlanta, GA.

The study found that response to therapy was high across cohorts, with 71 percent of previously untreated older patients experiencing a complete or partial response at either treatment dose (420mg and 840mg). The same response was observed in 67 percent of the relapsed patients and half (50%) of the high-risk patient cohort. After 22 months of follow-up, the disease had not progressed in 96 percent of previously untreated patients and 76 percent of relapsed and high-risk patients.

"These findings are truly exciting because they demonstrate ibrutinib's potential as a highly active, well-tolerated first-line therapy for CLL that produces a high rate of durable remissions the remissions last months on end," Byrd says. "The drug is effective in part because patients are willing to stay on treatment since the side effects are very tolerable," he states.

Only non-severe side effects, including diarrhea, fatigue, chest infection, rash, nausea, joint pain and infrequent and transient low blood counts were observed. Investigators found no evidence of c
'/>"/>

Contact: Liz Bryan, Spectrum
lbryan@spectrumscience.com
443-506-1931
Ohio State University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. EzCheckPrinting Updated with New Category Feature to Simplify Check Printing and Tax Reporting
2. Winning the battle against leukaemia: Positive early results in clinical trial for DNA vaccine
3. Pure Cocoa Powder, the Key Ingredient in Dark Chocolate and Found in Diabetes Support Supplements has been Clinically Proven to Reduce Cardiovascular Risk
4. USC Norris cancer research ranks among top clinical advances for 2012
5. American Society of Clinical Oncology issues annual report on state of clinical cancer science
6. Clinical trial at GHSU Cancer Center targets advanced prostate cancer
7. Study finds link between access to online health information and use of clinical services
8. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
9. Molecular portraits of tumours match patients with trials in everyday clinical practice
10. New targeted therapy for advanced prostate cancer shows anti-tumor activity in clinical trials
11. Spread of human melanoma cells in mice correlates with clinical outcomes in patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, 2014 (HealthDay ... herpes simplex -- might increase the risk of Alzheimer,s disease, ... a carrier of certain antibodies to the virus can double ... "The identification of a treatable cause [herpes simplex] of the ... Dr. Hugo Lovheim, an associate professor in the department of ...
(Date:10/25/2014)... News) -- Researchers who discovered antibiotics in farmed ... for concern. The use of antibiotics in ... consumption contribute to the development of antibiotic-resistant bacteria ... from the study. Each year in the ... people and kill about 23,000, according to the ...
(Date:10/25/2014)... News) -- Current osteoporosis screening guidelines and tools ... risk for osteoporosis-related fractures, a new study says. ... need tools that help us accurately predict who ... can target these at-risk people for preventive measures," ... in the division of general internal medicine and ...
(Date:10/25/2014)... (HealthDay News) -- October,s shorter, darker days can trigger ... according to an expert. People affected by ... tired, lack motivation and even have trouble getting out ... suicide, said Dr. Angelos Halaris, a professor in the ... Chicago Stitch School of Medicine. "Seasonal affective disorder ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 On Saturday, October ... its fourth annual family health and fitness fair ¡Vive tu ... physical activity and good nutrition for better health and wellness ... which is free and open to the public, will be ... Brownsville, from 9:00 am to 1:00 pm. , “¡Vive ...
Breaking Medicine News(10 mins):Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4
... Nutraceutics(TM) announces the addition of Jim and Julie ... marketing professionals. Their remarkable achievements and expertise are ... of worldwide, home-based business owners. Former Amway Quixtar ... throughout an impressive 28-year career. Jim and Julie ...
... Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ), ... commercialization of proprietary products that address important therapeutic needs ... of Joseph T. Kennedy to the position of Vice ... Mr. Kennedy will provide legal advice to the company ...
... Medical Center have joined forces to help provide area ... patient care. This new partnership is a unique program ... better handle the cumbersome and time-consuming issues of managing ... Center will use Physicians Practice,s extensive resources to deliver ...
... Medical Corporation today launched the third in a series ... Bruschi, a professional football player who suffered a stroke ... career. The new video features Tedy describing his personal ... a continuation of Tedy,s story that began with the ...
... Study suggests that fast-growing youth have greater fondness for treats, ... your children will eat only a few bites of dinner ... ice cream? , Blame it on their growing bones. , ... a higher preference for sweets than children growing at a ...
... Earn Decision Resources, Clinical Gold Standard Status for ... New Report from Decision ResourcesWALTHAM, Mass., March 25 ... research and advisory firms for pharmaceutical and healthcare ... therapy,s effect on the rate of mortality is ...
Cached Medicine News:Health News:Former Amway/Quixtar Diamond Leaders Find New Home at Eniva Nutraceutics 2Health News:Transcept Pharmaceuticals Appoints Joseph T. Kennedy as General Counsel 2Health News:Transcept Pharmaceuticals Appoints Joseph T. Kennedy as General Counsel 3Health News:Transcept Pharmaceuticals Appoints Joseph T. Kennedy as General Counsel 4Health News:Physicians Practice and Rose Medical Center Partner to Improve Patient Care in the Denver Metro Area 2Health News:Physicians Practice and Rose Medical Center Partner to Improve Patient Care in the Denver Metro Area 3Health News:AGA Medical Corporation Launches Third Web-Based Stroke Education and Awareness Video Featuring Professional Football Player Tedy Bruschi 2Health News:AGA Medical Corporation Launches Third Web-Based Stroke Education and Awareness Video Featuring Professional Football Player Tedy Bruschi 3Health News:A Child's Sweet Tooth May Be All in the Bones 2Health News:A Child's Sweet Tooth May Be All in the Bones 3Health News:Surveyed Experts Indicate that Biogen Idec's Adentri Has Advantages Over Nitroglycerin in the Treatment of Acute Heart Failure 2Health News:Surveyed Experts Indicate that Biogen Idec's Adentri Has Advantages Over Nitroglycerin in the Treatment of Acute Heart Failure 3
(Date:10/22/2014)... Oct. 22, 2014   Surefire Medical , Inc., ... designed to maximize targeted delivery of embolization agents in ... that oncologist John R. Daniels , MD of ... and surgical oncologist Steven C. Katz , MD ... Company,s Scientific Advisory Board (SAB).    "The ...
(Date:10/22/2014)... -- Sanomedics International Holdings, Inc. (OTCQB: SIMH) – According ... Data Services, demand for thermometers is expected to grow ... demand for more accurate digital thermometers continues.  ... market for thermometers, and one of the companies serving ... Inc. Sanomedics International Holdings designs, develops, markets, ...
(Date:10/22/2014)... AUSTIN, Texas , Oct. 22, 2014 ... announced they have entered into a license and ... to target cancers. PhosImmune possesses technology ... the surfaces of tumor cells in association with ... from proteins that play a role in malignancy, ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2
Straight shafts with fine Pierse type tips on a 5mm platform; In Titanium...
Smooth colibri tip; In Titanium....
Gently curved 5mm Platform With 12, 0.12mm Teeth; In Titanium....
Angled tip, 0.3mm triangular grasping tips; In Titanium....
Medicine Products: